{{About|藥劑地諾前列腺素|藥物地諾前列酮|前列腺素E2}}
{{多個問題|
{{cleanup-jargon|time=2014-06-23T18:23:34+00:00}}
{{copyedit|time=2014-06-23T18:23:34+00:00}}
{{roughtranslation|time=2014-06-23T18:23:34+00:00}}
}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 406310380
| IUPAC_name = (''Z'')-7-[(1''R'',2''R'',3''R'',5''S'')-3,5-dihydroxy-2-[(''E'',3''S'')- 3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
| image = Dinoprost.svg
| drug_name = Dinoprost Tromethamine

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|dinoprost-tromethamine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| routes_of_administration = [[靜脈注射|靜脈注射]] (促生產), [[羊膜腔|羊膜腔]]內注射 ([[墮胎|墮胎]])

<!--Pharmacokinetic data-->
| elimination_half-life = 3至6小時([[羊水|羊水]]內), 小於一分鐘([[血漿|血漿]])

<!--Identifiers-->
| CASNo_Ref = {{cascite}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 551-11-1
| CAS_supplemental = {{CAS|38562-01-5}}
| ATC_prefix = G02
| ATC_suffix = AD01
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4444062
|  smiles = O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC
|  InChI = 1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|  InChIKey = PXGPLTODNUVGFL-YNNPMVKQBA
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PXGPLTODNUVGFL-YNNPMVKQSA-N
| PubChem = 5280363
| IUPHAR_ligand = 1884
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01160
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D01352
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 815

<!--Chemical data-->
| C=20 | H=34 | O=5 
| molecular_weight = 354.48 g/mol
}}
''' [[前列腺素|前列腺素]] F<sub>2α </sub>''' ('''在[[前列腺素|前列腺素]]的命名中為PGF<sub>2α</sub>''')，其藥學上稱為'''地諾'''前列素([[International_Nonproprietary_Name|INN]])，它在醫學上的用途是作為天然的前列腺素用於[[引產|引產]]和墮胎藥。
在哺乳動物中，它是由子宮受刺激時產生的，因為卵泡期並沒有受精卵存在，子宮產生PGF2a。他作用於[[黃體|黃體]]導致黃體退化，形成了纖維化的[[卵巢白體|卵巢白體]]。PGF<sub>2α</sub>的作動是根據黃體模受體0的數目而進行。
該 PGF<sub>2α</sub> 亞型8-異前列腺素F<sub>2α</sub>被發現在子宮內膜異位症患者有顯卓的增加，因而是一種與子宮內膜異位相關的氧化應激潛在因子。<ref>{{cite journal|url=http://linkinghub.elsevier.com/retrieve/pii/S0015028209002611|pages=63–70|title=Role of 8-iso-prostaglandin F2α and 25-hydroxycholesterol in the pathophysiology of endometriosis|journal=Fertility and Sterility|volume=94|issue=1|accessdate=2018-04-02|doi=10.1016/j.fertnstert.2009.01.141|author=Indu Sharma, Lakhbir Kaur Dhaliwal, Subhash Chand Saha, Sonal Sangwan, Veena Dhawan}}</ref>

==作用機制==
更深入的資訊請見{{link-en|前列腺素F2alpha受体|Prostaglandin F2α receptor|前列腺素F<sub>2α</sub>受体}}

PGF<sub>2α</sub> 會和[[前列腺素F2α受體|前列腺素F2α受體]]結合。

==合成==
在2012年終，一個簡單並具有高選擇性的PGF<sub>2α</sub>合成出來了。<ref name="coulthard2012">{{cite journal|url=http://www.nature.com/articles/nature11411|pages=278–281|title=Stereocontrolled organocatalytic synthesis of prostaglandin PGF2α in seven steps|journal=Nature|volume=489|issue=7415|issn=1476-4687|date=2012/09|language=En|accessdate=2018-04-02|doi=10.1038/nature11411|author=Graeme Coulthard, William Erb, Varinder K. Aggarwal}}</ref>而這個合成只需要七個步驟，比先前Corey and Cheng<ref name="coreybook">{{cite book|title=The Logic of Chemical Synthesis|first1=E.J.|last1=Corey|first2=X.M.|last2=Cheng|publisher=Wiley|year=1995}}</ref>發表的十七個步驟進步許多。並使用2,5 -二甲氧基作為起始試劑，S – [[脯氨酸|脯氨酸]]作為不對稱催化劑。

==類似物==
下列藥物為[[前列腺素|前列腺素]] F<sub>2α</sub>的[[類似物|類似物]]:

{{link-en|拉坦前列素|Latanoprost}}

{{link-en|比馬前列素|Bimatoprost}}

{{link-en|曲伏前列素|Travoprost}}

{{link-en|卡前列素|Carboprost}}

==文獻資料==
{{Reflist}}
{{类花生酸类}}
[[Category:前列腺素类|Category:前列腺素类]]
[[Category:堕胎药|Category:堕胎药]]